Marseille, France, December 10, 2018 — Genoscience Pharma, a clinical-stage biotechnology company dedicated to discovering and developing anticancer drugs, is delighted to announce that it received the Most Innovative European Biotech SME Award for 2018 in the Healthcare category at EuropaBio.


Genoscience Pharma is an innovative SME located in Marseille, France. Its new therapy with an activity against cancer stem cells, which are considered to be responsible for treatment resistance, relapse and metastasis, is currently in an international Phase 1/2 trial in liver cancer (US and Europe). Genoscience Pharma’s drug candidate has the potential to be combined with any other anti-cancer therapy (chemotherapy, immunotherapy, targeted therapies and cell-gene therapy).


For the ninth edition of the EuropaBio Most Innovative European Biotech SME Awards, the members of the awards panel, Dr. Peter Heinrich, chair of EuropaBio’s SME platform; Dr. Andrew Porter from the University of Aberdeen; Dr. Paul Rübig, Austrian MEP and Joanna Dupont-Inglis, EuropaBio secretary general, assessed 40 companies from across the EU, acknowledging their outstanding contribution towards tackling significant challenges through the application of biotechnology.


In order to be considered for the EuropaBio SME awards, a company must qualify under the standard EU SME definition (e.g. primary location of operations within Europe, 250 or less employees, annual turnover of €50 Million ($56.8M) or less). EuropaBio awards companies and runners-up in three categories: healthcare, agricultural and industrial biotech. Biotech start-ups compete across all sectors in one special category recognizing early stage entrepreneurship. Each winner gets a cash prize plus two years free membership of EuropaBio. Both winners and runners-up also receive exposure in the EuropaBio network and the European biotech industry, as well as to top-level policy makers and industry leaders.


“Genoscience Pharma is delighted to receive such recognition of its work. We truly believe we can make the difference in cancer treatment with our innovative discovery, the first clinical-stage oral drug with an action on cancer stem cells. As we continue to face significant financing and regulatory barriers, this prize is an important opportunity to demonstrate our work. It will help us to further develop our technology,” said Philippe Halfon, CEO of Genoscience Pharma. “Cancer is probably the most important challenge for humanity. This recognition is one small step for our company but an important step in the fight against cancer.”


“For all the Genoscience Pharma team, this prize is a recognition of our hard work. We are delighted to see our efforts awarded, and this shows that no matter the size of a company, with motivation, strength and passion, we can reach our goals,” said Cindy Khaldi, translational science manager at Genoscience Pharma. “We are now looking forward to being able to spread our innovation worldwide to treat patients.”


About EuropaBio

The European Association for Bioindustries promotes an innovative and dynamic European biotechnology industry. EuropaBio and its members are committed to the socially responsible use of biotechnology to improve quality of life, to prevent, diagnose, treat and cure diseases, to improve the quality and quantity of food and feedstuffs and to move towards a biobased and zero-waste economy. EuropaBio represents 75 corporate members and 17 national biotechnology associations and bioregions.


About Genoscience Pharma

Genoscience Pharma is a French clinical-stage pharmaceutical company, focused on the discovery and development of novel anticancer first-in-class small molecules, to improve cancer treatment and clinical outcomes for patients. Genoscience Pharma plans to develop its products internationally, particularly in Europe, the US and Asia.


Forward-Looking Statements

This press release may involve and contain forward-looking statements by the company about its product candidate GNS561, including its potential benefits. Such statements are based upon the current beliefs and expectations of Genoscience Pharma’s management and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, but are not limited to: additional financing, the company’s ability to implement its chosen strategy, dependence upon third parties, other risks and uncertainties inherent in research and development, including the possibility of unfavorable study results, changes in the competitive environment, changes in regulations, clinical or industrial risks and all risks linked to the company’s growth. There are no guarantees that future clinical trials will be completed or successful or that any Genoscience Pharma therapeutics will receive regulatory approval for any indication or prove to be commercially successful. While those factors presented here are considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof; Genoscience Pharma does not undertake any obligation to update such statements to reflect subsequent events or circumstances.